PI3Kγ within a nonhematopoietic cell type negatively regulates diet-induced thermogenesis and promotes obesity and insulin resistance
Obesity is associated with a chronic low-grade inflammation, and specific antiinflammatory interventions may be beneficial for the treatment of type 2 diabetes and other obesity-related diseases. The lipid kinase PI3Kγ is a central proinflammatory signal transducer that plays a major role in leukocy...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 108; no. 42; pp. E854 - E863 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
18.10.2011
National Acad Sciences |
Series | PNAS Plus |
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 1091-6490 |
DOI | 10.1073/pnas.1106698108 |
Cover
Summary: | Obesity is associated with a chronic low-grade inflammation, and specific antiinflammatory interventions may be beneficial for the treatment of type 2 diabetes and other obesity-related diseases. The lipid kinase PI3Kγ is a central proinflammatory signal transducer that plays a major role in leukocyte chemotaxis, mast cell degranulation, and endothelial cell activation. It was also reported that PI3Kγ activity within hematopoietic cells plays an important role in obesity-induced inflammation and insulin resistance. Here, we show that protection from insulin resistance, metabolic inflammation, and fatty liver in mice lacking functional PI3Kγ is largely consequent to their leaner phenotype. We also show that this phenotype is largely based on decreased fat gain, despite normal caloric intake, consequent to increased energy expenditure. Furthermore, our data show that PI3Kγ action on diet-induced obesity depends on PI3Kγ activity within a nonhematopoietic compartment, where it promotes energetic efficiency for fat mass gain. We also show that metabolic modulation by PI3Kγ depends on its lipid kinase activity and might involve kinase-independent signaling. Thus, PI3Kγ is an unexpected but promising drug target for the treatment of obesity and its complications. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Author contributions: M.P.W. and G.S. designed research; B.B., R.M., F.Z., D.A., J.S., F.P., and G.S. performed research; J.-P.M. and B.T. contributed new reagents/analytic tools; B.B., R.M., F.Z., D.A., J.S., A.G.D., F.P., M.P.W., and G.S. analyzed data; and B.B., R.M., M.P.W., and G.S. wrote the paper. Edited* by Michael Karin, University of California at San Diego School of Medicine, La Jolla, CA, and approved August 30, 2011 (received for review April 29, 2011) 1B.B., R.M., F.Z., M.P.W., and G.S. contributed equally to this work. |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.1106698108 |